Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

PRAXIS PRECISION MEDICINES, INC.

(PRAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Praxis Precision Medicines to Present at Citi's 16th Annual BioPharma Virtual Conference

09/01/2021 | 09:01am EST

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance, today announced that management will participate in the ‘Emerging Therapies for Psychiatric Disorders’ panel at Citi’s 16th Annual BioPharma Virtual Conference on Wednesday, September 8, 2021 at 10:40 a.m. ET.

The panel will be available via live webcast through the Events & Presentations page of the Investors + Media section of the company’s website at www.praxismedicines.com. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders (CNS) characterized by neuronal imbalance. Praxis is applying insights from genetic epilepsies to broader neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio, including multiple disclosed programs across CNS disorders including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on LinkedIn and Twitter.


Investor Contact:
Alex Kane
Praxis Precision Medicines
investors@praxismedicines.com
617-300-8481

Media Contact:
Ian Stone
Canale Communications
Ian.stone@canalecomm.com
619-849-5388

Primary Logo


ę GlobeNewswire 2021
All news about PRAXIS PRECISION MEDICINES, INC.
11/29Praxis Precision Medicines to Present Data from Rare Disease Programs at the American E..
AQ
11/24Praxis Precision Medicines to Present at Piper Sandler's 33rd Annual Virtual Healthcare..
GL
11/04Wedbush Adjusts Price Target on Praxis Precision Medicines to $45 From $50; Outperform ..
MT
11/04Praxis Precision Medicines Files Mixed Shelf
MT
11/03Praxis Precision Medicines 3Q 2021 Corporate Update Call Presentation
PU
11/03Praxis Precision Medicines Q3 Loss Narrows
MT
11/03Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Fin..
PU
11/03PRAXIS PRECISION MEDICINES, INC. Management's Discussion and Analysis of Financial Con..
AQ
11/03Praxis Precision Medicines, Inc. Reports Earnings Results for the Third Quarter and Nin..
CI
11/03Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2021 Fin..
AQ
More news
Analyst Recommendations on PRAXIS PRECISION MEDICINES, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -158 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,61x
Yield 2021 -
Capitalization 761 M 761 M -
Capi. / Sales 2021 -
Capi. / Sales 2022 -
Nbr of Employees 67
Free-Float 98,6%
Chart PRAXIS PRECISION MEDICINES, INC.
Duration : Period :
Praxis Precision Medicines, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PRAXIS PRECISION MEDICINES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 17,11 $
Average target price 46,00 $
Spread / Average Target 169%
EPS Revisions
Managers and Directors
Marcio Souza President, Chief Executive Officer & Director
Timothy Edwin Kelly Chief Financial Officer & Treasurer
Dean Jonathan Mitchell Chairman
Bernard Ravina Chief Medical Officer
Steven Petrou Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
PRAXIS PRECISION MEDICINES, INC.-68.94%760
MODERNA, INC.252.74%149 412
LONZA GROUP AG28.41%58 671
IQVIA HOLDINGS INC.48.85%50 948
SEAGEN INC.-5.61%30 228
CELLTRION, INC.-42.34%24 321